Biography for Damian Garde
Damian Garde, Editor
Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at email@example.com and follow @DamianFierce on Twitter.
Articles by Damian Garde
Boehringer Ingelheim's in-development injection for psoriasis outpaced Johnson & Johnson's blockbuster Stelara in a Phase II trial, setting the table for late-stage development.
French drugmaker Servier has outlicensed some early-stage cancer treatments to Horizon Discovery, holding on to the rights to buy them back if they come through in preclinical development.
Merck KGaA and Pfizer, playing catch-up among drug companies using the immune system to fight cancer, picked up the FDA's fast-track designation for their in-development therapy, designed to expedite its eventual review.
Big Pharma has been willing to pay hundreds of millions of dollars for a shortcut to FDA approval, buying up priority review vouchers created to incentivize new drugs for neglected diseases. But the agency seems less than enthusiastic about honoring its end of the bargain, with one top official expressing concerns about how the voucher program might harm the FDA's core mission.
Dermatology drug developer Aclaris Therapeutics priced its IPO well below its expected range, raising $55 million as a prolonged bear turn has dampened Wall Street's appetite for biotech debuts.
Atlas Venture startup Quartet Medicine added $6.25 million to its Series A fundraise, closing the round at $23.25 million as it moves toward clinical trials with a newfangled way of treating chronic pain.
U.K. biotech Adaptimmune Therapeutics is expanding its ranks as it moves forward with a pipeline of cancer immunotherapies, leasing a big R&D facility near its native Oxford.
Axovant Sciences, rolling the dice on a once-failed Alzheimer's disease treatment, kicked off its big Phase III trial, a make-or-break effort that could spawn a blockbuster drug or liquidate the company's value.
Alkermes picked up FDA approval for a long-acting version of Otsuka's now-generic Abilify, planning to launch its injection as a treatment for schizophrenia.
Otonomy, developing treatments for ear disorders, got FDA clearance to start a clinical trial of its therapy for tinnitus.